Comparison of Virtual Reality, EMLA Cream, and Standard Care for Pain During Blood Draws in Children
Condition(s) studied
Investigational drug(s) / intervention(s)
Virtual Reality Distraction: Virtual reality distraction is provided during venipuncture using a Meta Quest 3 headset. All participants assigned to this intervention view the same 360° wildlife video. Children can change the direction of view by moving their head but cannot control the content or sequence of the video. The headset is used throughout the venipuncture procedure.
Lidocaine-Prilocaine Cream: Topical EMLA cream containing lidocaine and prilocaine is applied to the planned venipuncture site, covered with an occlusive dressing, and left in place for at least 60 minutes before venipuncture.
Study summary
This randomized controlled trial evaluates methods to reduce pain during venipuncture in children aged 3 to 15 years. The study compares three approaches: virtual reality distraction using a VR headset, topical anesthesia with EMLA cream, and standard care without an additional pain-reducing intervention. The main question is whether virtual reality reduces pain during venipuncture more effectively than EMLA cream or standard care. Pain is assessed immediately after venipuncture using the Wong-Baker Faces Pain Rating Scale (0-10). The planned study sample includes 450 children.
Eligibility
Primary outcome measure(s)
- Pain Intensity During Venipuncture — Immediately after venipuncture
Pain intensity is self-reported immediately after venipuncture using the Wong-Baker Faces Pain Rating Scale (0-10), where 0 indicates no pain and 10 indicates the worst pain. Lower scores indicate lower perceived pain intensity.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem | Ústí nad Labem | Ústí nad Labem Region | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07763132 on ClinicalTrials.gov ↗ ← All trials in Czechia